Fate Therapeutics has initiated and treated the first patient in RECLAIM-LN, a Phase II clinical trial evaluating FT819 in patients with moderate-to-severe SLE with Class III or IV lupus nephritis.

The post Fate Therapeutics begins Phase II trial of FT819 for lupus nephritis appeared first on Clinical Trials Arena.